A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä
18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer




Julkaisun tekijät: Komar G, Seppänen M, Eskola O, Lindholm P, Grönroos TJ, Forsback S, Sipilä H, Evans SM, Solin O, Minn H.
Kustantaja: Society of Nuclear Medicine and Molecular Imaging
Julkaisuvuosi: 2008
Lehden akronyymi: J Nucl Med
Volyymi: 49
Julkaisunumero: 12

Tiivistelmä

The aim of this study
was to evaluate
2-(2-nitro-(1)H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)-acetamide
(EF5) labeled with (18)F-fluorine to image hypoxia in patients with
squamous cell carcinoma of the head and neck (HNSCC).

METHODS:

Fifteen
patients with HNSCC were studied. Measurement of tumor blood flow was
followed by an (18)F-EF5 PET/CT scan. On a separate day, (18)F-FDG
PET/CT was performed to determine the metabolically active tumor volume.
In 6 patients, dynamic (18)F-EF5 images of the head and neck area were
acquired, followed by static images acquired at 1, 2, and 3 h after
injection. In the remaining 9 patients, only static images were
obtained. (18)F-EF5 uptake in tumors was compared with that in neck
muscle, and the (18)F-EF5 findings were correlated with the (18)F-FDG
PET/CT studies.

RESULTS:

A
total of 13 primary tumors and 5 lymph node metastases were evaluated
for their uptake of (18)F-EF5. The median tumor-to-muscle (18)F-EF5
uptake ratio (T/M) increased over time and was 1.38 (range, 1.1-3.2) 3 h
after tracer injection. The median blood flow in tumors was 36.7 mL/100
g/min (range, 23.3-78.6 mL/100 g/min). Voxel-by-voxel analysis of
coregistered blood flow and (18)F-EF5 images revealed a distinct
pattern, resulting in a T/M of 1.5 at 3 h to be chosen as a cutoff for
clinically significant hypoxia. Fourteen of 18 tumors (78%) had
subvolumes within the metabolically active tumor volumes with T/M
greater than or equal to 1.5.

CONCLUSION:

On
the basis of these data, the potential of (18)F-EF5 to detect hypoxia
in HNSCC is encouraging. Further development of (18)F-EF5 for eventual
targeting of antihypoxia therapies is warranted.


Last updated on 2019-30-01 at 00:35